Acetyl-Histone H3 (K9) Antibody

What is Acetyl-Histone H3 (K9) Antibody and its significance in epigenetic research?

Acetyl-Histone H3 (K9) antibody is a specialized research tool that specifically recognizes histone H3 acetylated at lysine 9 (H3K9ac). This post-translational modification plays a crucial role in gene activation and chromatin remodeling, making this antibody essential for studying gene expression regulation .

Histone H3K9 acetylation serves as a key epigenetic mark associated with transcriptionally active regions of the genome. As a core component of nucleosomes, histone H3 contributes to DNA packaging into chromatin, where its acetylation status directly affects DNA accessibility to transcriptional machinery . The specificity of these antibodies allows researchers to distinguish H3K9ac from other acetylated lysines in histone H3, providing precise insights into specific epigenetic mechanisms .

What applications can Acetyl-Histone H3 (K9) Antibody be utilized for in laboratory research?

Acetyl-Histone H3 (K9) antibodies support multiple research applications across epigenetic investigations:

These diverse applications enable researchers to comprehensively analyze H3K9 acetylation status in various experimental contexts and model systems .

How should samples be prepared for optimal H3K9ac detection?

Optimal sample preparation is critical for reliable H3K9ac detection. Based on experimental evidence:

• Blood samples: For peripheral blood analysis, immediate processing is recommended. Leukocytes should be isolated within 24 hours of collection to maintain histone acetylation status. Storage of blood at room temperature for extended periods results in degradation of acetylation marks .

• Cell culture treatments: Treatment with histone deacetylase inhibitors (HDACi) such as sodium butyrate (for cell lines) or trichostatin A (TSA) at 1 μM for 18 hours significantly increases H3K9ac levels, providing positive controls for antibody validation .

• Protein extraction: For Western blot analysis, acid extraction methods are preferred for enriching histone proteins. Using 25 μg of protein per lane typically provides sufficient signal when using antibody dilutions of 1:1000 .

• Fixation for microscopy: For immunocytochemistry, 4% formaldehyde fixation for 10 minutes followed by permeabilization with PBS/TX-100 containing 5% normal goat serum and 1% BSA yields optimal results .

Following these preparation methods ensures consistent and reliable detection of H3K9ac across different experimental platforms.

What controls should be included when using Acetyl-Histone H3 (K9) Antibody?

Proper experimental controls are essential for accurate interpretation of results with H3K9ac antibodies:

• Positive controls: Include samples treated with histone deacetylase inhibitors (HDACi) such as sodium butyrate, TSA, or LBH589, which increase global histone acetylation levels .

• Negative controls: Use IgG from the same species as the primary antibody (typically rabbit) at equivalent concentration for immunoprecipitation controls .

• Loading controls: For Western blotting, β-actin (42 kDa) serves as an appropriate loading control, while total histone H3 can provide normalization for specific acetylation levels .

• Specificity controls: When possible, include peptide competition assays or dot blots with acetylated and non-acetylated peptides to confirm antibody specificity .

• Cross-reactivity assessment: Verify that the antibody does not cross-react with other acetylated lysines in histone H3, particularly K4ac, K14ac, K18ac, K23ac, K27ac, K36ac, K56ac, K79ac, or K122ac .

Including these controls helps validate results and ensures the observed signals specifically represent H3K9 acetylation.

What are the optimal protocols for ChIP experiments using Acetyl-Histone H3 (K9) Antibody?

Chromatin immunoprecipitation with H3K9ac antibodies requires specific optimization for successful outcomes:

Recommended ChIP Protocol:

• Chromatin preparation: Cross-link cells with 1% formaldehyde for 10 minutes at room temperature, followed by quenching with glycine.

• Sonication: Shear chromatin to fragments of 200-500 bp, verified by agarose gel electrophoresis.

• Antibody amount: Use 5 μg of H3K9ac antibody per ChIP reaction with chromatin from approximately 1 million cells .

• Controls: Include an IgG control (2 μg/IP) as a negative control .

• Validation: Analyze immunoprecipitated DNA by qPCR using primers for:

  • Positive controls: Promoters of actively transcribed genes (GAPDH, c-fos)

  • Negative controls: Inactive genes (MB) or heterochromatic regions (Sat2 satellite repeat)

For ChIP-seq applications, library preparation should follow standard protocols with 36 bp tags aligned to the reference genome using appropriate algorithms such as ELAND . Peak analysis typically reveals H3K9ac enrichment at promoters of active genes, consistent with its role in gene activation.

How can researchers distinguish between H3K9ac and other histone acetylation marks?

Distinguishing H3K9ac from other histone acetylation marks requires careful antibody selection and validation:

• Antibody specificity testing: Use dot blot analysis with a panel of modified histone peptides to confirm recognition of only H3K9ac. High-quality antibodies should detect the mono-acetylated peptide corresponding to H3K9ac without cross-reacting with unacetylated Histone H3 or other acetylated lysines .

• Western blot confirmation: Observe a single band at approximately 15-16 kDa corresponding to acetylated histone H3 . Multiple bands may indicate non-specific binding.

• Peptide competition assays: Pre-incubation of the antibody with acetylated peptides should abolish specific signals.

• Comparative analysis: When studying multiple acetylation marks, use antibodies that have been validated against a complete panel of modified peptides to ensure specificity .

• Sub-nuclear localization: Different acetylation marks may show distinct nuclear distribution patterns. For instance, H3K9ac appears more localized to the periphery of the nucleus while H4 acetylation shows more concentrated nuclear staining .

These approaches help ensure that observed signals are specific to H3K9ac rather than other histone modifications.

How do treatments with histone deacetylase inhibitors affect H3K9ac detection?

Histone deacetylase inhibitors (HDACi) significantly impact H3K9ac levels and detection, making them valuable tools for research:

• Sodium butyrate treatment: Treating HeLa cells with sodium butyrate substantially increases H3K9ac levels, providing a positive control for antibody validation in Western blot, immunocytochemistry, and other applications .

• TSA (Trichostatin A) treatment: Application of 1 μM TSA to cells (NIH/3T3, C6) for 18 hours at 37°C significantly enhances H3K9ac signals in Western blot and immunofluorescence analyses .

• LBH589 effects: This clinical HDACi increases histone acetylation in peripheral blood leukocytes, with effects detectable by Western blot, flow cytometry, and immunohistochemistry. LBH589 treatment serves as a positive control in clinical samples .

• Quantitative analysis: Western blot membranes can be scanned and H3K9ac signals normalized to reference proteins (e.g., β-actin) to quantify increases in acetylation following HDACi treatment. Typically, the fold change in acetylation is calculated relative to a reference sample .

• Time-course considerations: The timing of sample collection following HDACi treatment is critical, as acetylation levels may vary. For most applications, 18-24 hours of treatment provides robust increases in H3K9ac .

This manipulation of acetylation status using HDACi provides important experimental controls and models for epigenetic regulation studies.

What methodologies exist for quantitative analysis of H3K9ac in clinical samples?

Several methodologies have been developed specifically for quantitative analysis of H3K9ac in clinical samples:

• Flow cytometric method:

  • Peripheral blood mononuclear cells are isolated by Ficoll-Paque separation

  • Cells are fixed, permeabilized, and stained with H3K9ac antibodies

  • Flow cytometry allows quantification of acetylation levels in different cell populations

  • This method is particularly suitable for monitoring histone acetylation in isolated lymphocytes and liquid tumors

• Western blot quantification:

  • Leukocyte cell pellets are lysed in protein lysis buffer

  • Acetylated histone H3 appears as a band at approximately 16 KDa

  • Loading controls (β-actin) adjust for concentration variations

  • Quantification involves scanning membranes and normalizing to reference proteins

• Immunohistochemistry/Immunocytochemistry:

  • Mononuclear cells are separated, treated, and cyto-spun onto slides

  • Acetylation is detected using anti-acetylated histone antibodies

  • Confocal microscopy with digitized images allows visualization of nuclear localization patterns

  • H3K9ac typically shows more peripheral nuclear localization compared to other modifications

These methods provide complementary approaches for monitoring H3K9ac in patient samples, particularly in the context of clinical trials involving HDACi treatments .

How does H3K9ac interact with other epigenetic modifications in regulating gene expression?

H3K9 acetylation functions within a complex network of epigenetic modifications:

• Relationship with other histone marks: H3K9ac often co-occurs with other active chromatin marks such as H3K4 methylation and H3K27ac at promoters of actively transcribed genes. Genome-wide ChIP-seq analysis demonstrates that H3K9/14 double acetylation is enriched at promoters of active genes like GAPDH and c-fos .

• Antagonistic modifications: H3K9ac is generally mutually exclusive with repressive modifications at the same residue, particularly H3K9 methylation, which is associated with heterochromatin formation and gene silencing.

• Chromatin remodeling interactions: H3K9ac facilitates the recruitment of chromatin remodeling complexes that maintain open chromatin structure. This modification helps regulate DNA accessibility to transcriptional machinery .

• Temporal dynamics: During cellular differentiation or response to environmental stimuli, H3K9ac levels at specific genomic loci change dynamically in coordination with other histone modifications to regulate gene expression programs.

• Enzyme interactions: Histone acetyltransferases (HATs) like p300 establish H3K9ac marks, while histone deacetylases (HDACs) remove them. The LANCE Ultra Europium-anti-acetyl-Histone H3 Lysine 9 antibody has been used to develop assays for p300 acetyltransferase activity using biotinylated Histone H3 peptides as substrates .

Understanding these interactions provides insight into the complex regulatory mechanisms controlling gene expression through epigenetic modifications.

What are the technical challenges in analyzing histone acetylation in blood samples and how can they be overcome?

Analysis of histone acetylation in blood samples presents several technical challenges:

• Sample stability: Histone acetylation marks in blood can degrade over time. Research shows that processing samples immediately after collection is critical. If immediate processing is impossible, samples should be stored at 4°C and processed within 24 hours to preserve acetylation status .

• Processing methods comparison: Different blood processing methods affect histone acetylation detection:

  • Ficoll-Paque separation of mononuclear cells provides cleaner samples but requires more processing time

  • Red blood cell lysis methods are faster but may introduce more contaminants
    Both methods adequately preserve histone acetylation when samples are processed promptly

• Cell-type heterogeneity: Blood contains multiple cell types with different baseline histone acetylation levels. Flow cytometry with appropriate gating strategies can distinguish acetylation levels in different leukocyte populations.

• Quantification challenges: For Western blot analysis, normalization to loading controls (β-actin) is essential. For flow cytometry, appropriate isotype controls must be included .

• HDACi exposure effects: In clinical trials involving HDACi, blood collection timing relative to drug administration affects acetylation levels. Standardized collection protocols are necessary for comparable results across patients.

• Clinical correlation limitations: While these methods effectively monitor blood cell responses to HDACi treatment, the correlation between blood cell histone acetylation and tumor responses or clinical outcomes requires careful interpretation. Blood cell histone acetylation may not necessarily reflect acetylation changes in solid tumors or disease-relevant tissues .

Addressing these challenges through standardized protocols ensures more reliable histone acetylation analysis in clinical blood samples.

Table 1: Comparison of Acetyl-Histone H3 (K9) Antibody Types and Applications

Table 2: Recommended Dilutions/Concentrations for Different Applications

Table 3: H3K9ac Enrichment at Gene Promoters (ChIP-qPCR Data)